Mylan Pharmaceuticals Inc. has voluntarily recalled approximately 48,680 bottles of Nizatidine (150 mg and 300 mg) capsules, a prescription medication used to treat ulcers and GERD. Trace amounts of an impurity called N-nitrosodimethylamine (NDMA) were detected in the active pharmaceutical ingredient. These medications were distributed nationwide to wholesalers, retail pharmacies, and mail-order pharmacies between January 2020 and May 2021. Consumers should consult their healthcare provider for an alternative treatment and return the affected product to their pharmacy for a refund.
NDMA is classified as a probable human carcinogen. While trace amounts were detected, the impurity is a substance that could increase the risk of cancer over long-term exposure.
Pharmacy refund and medical consultation
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.